{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T20:57:52Z","timestamp":1649019472169},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1053\/j.semtcvs.2014.12.005","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T11:49:56Z","timestamp":1419421796000},"page":"323-330","source":"Crossref","is-referenced-by-count":4,"title":["Current Readings: Window-of-Opportunity Trials for Thoracic Malignancies"],"prefix":"10.1053","volume":"26","author":[{"given":"Anne S.","family":"Tsao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semtcvs.2014.12.005_bib1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data","volume":"383","author":"NSCLC Meta-Analysis Collaborative Group","year":"2014","journal-title":"Lancet"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib3","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1200\/JCO.2003.11.040","article-title":"Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: A multicenter phase II trial","volume":"21","author":"Betticher","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib4","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6603075","article-title":"Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-Year follow-up of a phase II study","volume":"94","author":"Betticher","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/PPO.0b013e318299f647","article-title":"Surgical approach to locally advanced non-small cell lung cancer","volume":"19","author":"Donington","year":"2013","journal-title":"Cancer J"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib6","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1200\/JCO.2009.22.3370","article-title":"Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer","volume":"27","author":"Lara-Guerra","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib7","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1158\/1078-0432.CCR-10-2102","article-title":"Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene","volume":"17","author":"Rizvi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib8","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib9","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib10","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1200\/JCO.2009.23.9749","article-title":"Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I\/II resectable non-small-cell lung cancer","volume":"28","author":"Altorki","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib11","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-09-2533","article-title":"Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib","volume":"70","author":"Nikolinakos","year":"2010","journal-title":"Cancer Res"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","article-title":"Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma","volume":"7","author":"Machtay","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients\u05f3 data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials","volume":"13","author":"Pazdur","year":"2008","journal-title":"Oncologist"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/JTO.0b013e3182835549","article-title":"FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies","volume":"8","author":"Benveniste","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/annonc\/mds537","article-title":"Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma","volume":"24","author":"Tsutani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.acra.2011.12.010","article-title":"Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: Prognostic implication focused on histopathologic subtypes","volume":"19","author":"Lee","year":"2012","journal-title":"Acad Radiol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib18","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1158\/1535-7163.MCT-07-0052","article-title":"Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion","volume":"6","author":"Tsao","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/JTO.0b013e3182774108","article-title":"Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy","volume":"8","author":"William","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib20","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.2012.45.8703","article-title":"Harnessing the immune system for the treatment of non-small-cell lung cancer","volume":"31","author":"Brahmer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib21","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8021","article-title":"Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC","volume":"32","author":"Brahmer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/CMAR.S57550","article-title":"New modalities of cancer treatment for NSCLC: Focus on immunotherapy","volume":"6","author":"Davies","year":"2014","journal-title":"Cancer Manage Res"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib24","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S1470-2045(12)70126-2","article-title":"Immunotherapies for non-small-cell lung cancer and mesothelioma","volume":"13","author":"Thomas","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semtcvs.2014.12.005_bib25","first-page":"S7","article-title":"Programmed cell death 1 ligand 1 expression and association with survival in mesothelioma","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"}],"container-title":["Seminars in Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043067914001312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043067914001312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T20:28:48Z","timestamp":1566160128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043067914001312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"alternative-id":["S1043067914001312"],"URL":"https:\/\/doi.org\/10.1053\/j.semtcvs.2014.12.005","relation":{},"ISSN":["1043-0679"],"issn-type":[{"value":"1043-0679","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}